Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lowering the boom on lower-risk myelodysplastic syndromes.

Hematology. American Society of Hematology. Education Program - 6 Dec 2019

Sekeres Mikkael A, Patel Bhumika J

Abstract excerpt

Lower-risk myelodysplastic syndromes are defined using prognostic scoring systems that incorporate data on bone marrow blast percentage, degree and numbers of cytopenias, and cytogenetic abnormalities. Increasingly, these are incorporating molecular abnormalities to further refine risk. Therapy is geared toward predominating cytopenias, with erythropoiesis-stimulating agents luspatercept and lenalidomide used to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activin Receptors, Type II
Share to Benzoates
Share to Hydrazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Fc Fragments

Share to Lenalidomide

Share to Myelodysplastic Syndromes

Share to Pyrazoles

Share to Thrombocytopenia

Source

Open in PubMed Open full text

Identifiers

PMID: 31808873
DOI: 10.1182/hematology.2019000040
PMCID: PMC6913460

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lowering the boom on lower-risk myelodysplastic syndromes.PMID 31808873Read ↗

Therapy for lower-risk MDS.Semantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

Current therapeutic approaches for patients with myelodysplastic syndromes.Semantic proximity Read ↗

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.Semantic proximity Read ↗

Myelodysplastic syndromes.Semantic proximity Read ↗

Updates in Risk Stratification in Myelodysplastic Syndromes.Semantic proximity Read ↗

How I treat higher-risk MDSSemantic proximity Read ↗

Myelodysplastic Syndromes: A New Decade.Semantic proximity Read ↗

Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges.Semantic proximity Read ↗

Myelodysplastic Neoplasms (MDS): The Current and Future Treatment LandscapeSemantic proximity Read ↗

The current and future role of stem cells in myelodysplastic syndrome therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.